Abstract

Background: IL-33, one of the IL-1 superfamily cytokines, has been shown to be associated with pruritus and inflammation in atopic dermatitis (AD). Furthermore, IL-33 production derived from keratinocytes reportedly has a crucial role in the development of AD; however, the mechanism of IL-33 expression has not been fully understood. Methods: We analyzed IL-33 expression in normal human epidermal keratinocytes (NHEKs) treated with IL-4. Results: IL-4 induced the upregulation of IL-33 expression in NHEKs. Based on the findings 1) that ovo-like 1 (OVOL1), a susceptible gene of AD, upregulates filaggrin (FLG) and loricrin (LOR) expression in NHEKs and 2) that reduced expression of FLG and LOR leads to production of IL-1 superfamily cytokines, we examined the involvement of OVOL1 in IL-33 expression in NHEKs. Knockdown of OVOL1 induced upregulation of IL-33 expression. Moreover, because Glyteer, an activator of aryl hydrocarbon receptor (AHR), reportedly upregulates OVOL1 expression, we examined whether treatment with Glyteer inhibited IL-33 expression in NHEKs. Treatment with Glyteer inhibited IL-4-induced upregulation of IL-33 expression, which was canceled by knockdown of either AHR or OVOL1. Conclusions: Activation of the AHR-OVOL1 axis inhibits IL-4-induced IL-33 expression, which could be beneficial for the treatment of AD.

Highlights

  • Atopic dermatitis (AD) is characterized by pruritus, cutaneous inflammation, and dry skin with epidermal barrier dysfunction [1]

  • Based on our previous finding that the activation of aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, upregulates OVO-like 1 (OVOL1) expression [11,12,13], we examined whether the activation of AHR by Glyteer, a soybean tar that is utilized for AD treatment clinically in Japan [16,17], inhibited IL-4-induced IL-33 expression in normal human epidermal keratinocytes (NHEKs)

  • To investigate the regulatory mechanism of IL-33 expression induced by IL-4, a key cytokine in the pathogenesis of AD [1], we examined this expression in NHEKs treated with IL-4

Read more

Summary

Introduction

Atopic dermatitis (AD) is characterized by pruritus, cutaneous inflammation, and dry skin with epidermal barrier dysfunction [1]. It has been reported that IL-33 expression is increased in the epidermis of patients with AD [5] and that IL-33 production derived from keratinocytes has an important role in the development of AD-like skin lesions in experimental murine models [6,7]. This suggests the benefits of revealing the regulatory mechanism of IL-33 expression in keratinocytes, which could enable the control of pruritus and cutaneous inflammation in AD. These findings suggest that activation of the AHR-OVOL1 axis exerts an inhibitory effect on IL-33 expression induced by IL-4, which contributes to attenuate pruritus and disease activity in AD

Reagents and Antibodies
Cell Culture
Immunofluorescence and Confocal Laser Scanning Microscopy
Transfection with siRNAs against AHR and OVOL1
Western Blotting Analysis
IL-4 Induces Upregulation of IL-33 Expression in NHEKs
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call